The evolution of the COVID-19 pandemic in paediatric patients with sickle cell disease: From Alpha to Omicron
British journal of haematology
COVID-19; clinical research; pediatrics; sickle cell disease
We compare the impact of SARS-CoV-2 variants on healthcare utilization and clinical presentation in paediatric patients with sickle cell disease (SCD). One hundred and ninety-one unique patients with SCD and positive SARS-CoV-2 polymerase chain reactions were identified between March 2020 and January 2022. Hospitalizations, which accounted for 42% (N = 81) of cases, were highest during the Delta dominant era (48%) and lowest during Omicron (36%) (p = 0.285). The most common SCD-related complication was vaso-occlusive pain (37%, N = 71), which accounted for 51% of all hospital admissions (N = 41), and acute chest was highest in the Alpha variant era (N = 15). Overall, COVID-19 remained mild in clinical severity within most paediatric SCD patients.
Martin, Olufunke Y.; Margulies, Stefanie; Speller-Brown, Barbara; Majumdar, Suvankar; Darbari, Deepika S.; and Campbell, Andrew D., "The evolution of the COVID-19 pandemic in paediatric patients with sickle cell disease: From Alpha to Omicron" (2023). GW Authored Works. Paper 2867.